Article

May 29, 2012

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos

H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview

Dr Kimlin Tam Ashing

Naim Alkhouri, MD

Jaime Almandoz, MD, MBA

Martin Edelman, MD

Pierluigi Porcu, MD

Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com

JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)

Elizabeth Grush, MBA

Related Content

Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com

April 30th 2025

Keep Patients at the Center of Clinical Research

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

The complex interplay between RA and metabolic health can have a significant impact on morbidity and mortality and thus deserves attention, authors of a new review argued. | Image credit: 9nong - stock.adobe.com

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

Alopecia areata. | Image Credit: cattyphoto - stock.adobe.com

April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

Jared Kaltwasser

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Related Content

Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com

April 30th 2025

Keep Patients at the Center of Clinical Research

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

The complex interplay between RA and metabolic health can have a significant impact on morbidity and mortality and thus deserves attention, authors of a new review argued. | Image credit: 9nong - stock.adobe.com

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

Alopecia areata. | Image Credit: cattyphoto - stock.adobe.com

April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

Jared Kaltwasser

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions